Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47 per cent more weight than those who were given Novo Nordisk’s Wegovy in the first large, head-to-head trial of the highly in-demand rival medicines.
In the 751-person trial sponsored by Lilly, Zepbound helped patients lose an average of 20.2 per cent of their weight after 72 weeks compared to 13.7 per cent for the group treated with Wegovy, Lilly said.
Participants were either obese or overweight and had an additional related health issue such as obstructive sleep apnoea or heart disease. None of the trial subjects had diabetes.
The data comparing the wildly popular medicines shows for the first time that when trial parameters are exactly the same, Lilly’s drug is more effective for weight loss, the company said.
Shopping centres, apartments and logistics: the top commercial property deals of 2024
Buy now, pay later: Many don’t realise that buying clothes with services like Klarna is taking out a loan
Mixed figures on home completions and business will miss the Greens now they’re gone
Can my employer baldly state that its policy is different from whatever the employee handbook says?
Shares in Eli Lilly rose 1.7 per cent to $827.19 in premarket trading, while Novo Nordisk’s Copenhagen-listed shares fell 1.4 per cent.
US regulatory approval for the medicines was based on separate trials in which Zepbound helped patients lose more than 22 per cent of their overall weight after 72 weeks, while Wegovy led to a 15 per cent weight loss after 68 weeks.
Doctors in the US had been prescribing the drugs based on whichever was available to patients at the pharmacy given intermittent supply shortages.
The most common side effects for both the drugs were related to the gastrointestinal system and were generally mild-to-moderate in severity, Lilly said.
The results may persuade insurers in the US and cost-conscious health authorities in Europe to give preferential coverage to Zepbound over Wegovy, as health authorities in Britain considered doing earlier this year before approving Lilly’s drug.
An analysis of health records and other data published by the medical journal JAMA Internal Medicine earlier this year showed Zepbound led to faster and greater weight loss than Wegovy.
US-based Lilly and Danish rival Novo Nordisk have been in a race to get their obesity drugs approved to treat other ailments to help improve acceptance by insurers and governments. Wegovy was approved in the US as a treatment for heart disease in March, while Zepbound is expected to be given the green light as a treatment for obstructive sleep apnoea.
Both drugs are sold in the US under different brand names – Novo’s Ozempic and Lilly’s Mounjaro – to treat type 2 diabetes. – Reuters
